ClinicalTrials.gg
Status unknownNCT02633436Updated Aug 12, 2016

Research on the Role of SLC1A5 in the Development of Esophageal Cancer

An observational study in Esophageal Cancer and Amino Acid Transport Disorder, sponsored by Fourth Affiliated Hospital of Guangxi Medical University. Status unknown at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-12.

Sponsored by Fourth Affiliated Hospital of Guangxi Medical University · Observational

How we know

The sponsor has not verified this record recently (last verified Aug 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 502 studies in Esophageal Neoplasms with a site in China — 211 open to participants now, 238 under way, 28 of them phase 3. Esophageal Neoplasms · China.

Planned enrollment
83rd of 108
100 · median 300
Started
2015
with 25 others
Observational
108 of 502
44 open now
Registered
85th of 502
by date

Among the 502 studies in Esophageal Neoplasms with a site in China, this one is the 83rd largest by planned enrollment of the 108 observational ones that give a count, is one of 26 that started in 2015, is one of 108 observational ones, and was the 85th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

211 of the 502 studies in Esophageal Neoplasms with a site in China are open now. Recruiting first, the newest first:

206 more — sign in →

All 211 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 502 studies in Esophageal Neoplasms with a site in China, or all of them as a file.
02

Study summary

To explore the significance of Solute Carrier Family 1 Member 5 (SLC1A5) in the occurrence of esophageal cancer, by comparing the expression of SLC1A5 between esophageal cancer tissues and adjacent tissues.

Read the detailed description

This will be an observational study. The investigators will aim to enroll 100 male and female adult patients (aged 18 years and over) of all ethnicities/races, who have been referred to the Fourth Affiliated Hospital of Guangxi Medical University for esophageal cancer.

The investigators will be using a standardized data collection form. This is an observational study in which standard of care will be practiced and the patients are not placed at additional risk from participating in this study. However, as the investigators are collecting data prospectively, all participants will sign consent. An attempt will be made to see if there is a correlation between the expression of SLC1A5 with esophageal cancer.

03

Conditions studied

  • Esophageal Cancer
  • Amino Acid Transport Disorder

Keywords

  • esophageal cancer
  • SLC1A5
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with histologically proven esophageal cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with proven esophageal cancer;
  2. Age ≥18 years;
  3. All patients must sign consent forms voluntarily;

Exclusion criteria

Exclusion Criteria:

  1. Inability to obtain histologic proof of .
  2. Age \<18 years;
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-only
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • cancer tissues

    SLC1A5 expression of esophageal cancer tissues from patients

    Other: SLC1A5 expression

  • paired adjacent tissues

    SLC1A5 expression of paired adjacent esophageal tissues from patients

    Other: SLC1A5 expression

Interventions

  • OtherSLC1A5 expression

    To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.

06

What researchers measure

Primary outcomes

  1. optical density (ODs) of each slice by immunohistochemistry assay

    For immunohistochemistry assay: Briefly, the samples will be cut into slices, which will be stained with standard steps. Finally, three high power fields will be randomly selected from each slice and the average optical density (OD) will be measured in each field.

    Time frame: within one year (plus or minus 1 month) after surgery

Secondary outcomes

  1. SLC1A5 expression detected by WesternBlot

    Western blot assay will be done by comparing the intensity of bands. To start with, xray film will be scanned on a flat-bed scanner. Then the grayscale image will be analyzed with software. Finally the Gray Value of each band will be obtained for analysis.

    Time frame: within one year (plus or minus 1 month) after surgery

07

Study locations

2 of 2 sites recruiting
  • Liuzhou Maternity and Child Healthcare Hospital
    Liuzhou, Guangxi 545000, China
    Recruiting
  • The Fourth Affiliated Hospital of Guangxi Medical University
    Liuzhou, Guangxi 545000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Jul 2018 and a completion of Aug 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2015
First posted
Dec 17, 2015
Start
Dec 2015
Primary completionEst.
Jul 2018
CompletionEst.
Aug 2018
Last update
Aug 12, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02633436
Lead sponsor
Fourth Affiliated Hospital of Guangxi Medical University
Collaborators
Liuzhou Maternity and Child Healthcare Hospital
Responsible party
Sponsor
First posted
Dec 17, 2015
Start date
Dec 2015
Primary completion
Jul 2018 (estimated)
Completion
Aug 2018 (estimated)
Last update
Aug 12, 2016

Study contacts

Shengming Dai, Dr.
Contact
daishm@sina.com
+86 13978026884
Zheng Peng
Contact
labstar@qq.com
+86 18589966550
Xiangcheng Wei
principal investigator · Guangxi Medical University Institutional Review Board

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion